Rizer XL™ Official Clinical Trial Results

Rizer XL™ Clinical Trial

The makers Rizer XL™ conducted a 6 month clinical study involving 87 healthy males ages ranging from 18-72 experiencing either mild to severe cases of erectile dysfunction. Symptoms of erectile dysfunction range from the inability to achieve or maintain an erection, premature ejaculation, the inability to ejaculate and below average libido levels. The study, conducted under the supervision of Dr. Ginsburg, included volunteer males free of any major health issues and lack of any prescribed medication that would hinder the results.

The study was divided into three groups (groups A-B-C), each group containing an equal amount of age to weight ratio with each group prescribed a different supplement and monitored over a 6 months period. Group A was administered Rizer XL™ in its recommended dosage of one tablet daily. Group B was administered 1 sugar pill daily and Group C was given a selection of their choice of either Viagra or Levitra. Results were charted and noted biweekly for 6 months from the volunteers under the strict supervision of urologist Dr. Ginsburg. Patients from all groups reported erection size, strength and frequency. Ejaculate amounts were measured and levels of ejaculate control were also reported. At the end of the trial period there were sticking differences of significant sizes between each group. Group A appeared to have the highest results followed by C and group B respectively. Patients consuming Rizer XL™ on a daily basis exhibited the highest results ranging from instant erections, maintaining of erection through entire sexual encounters, dramatic libido increase, total ejaculation control and significant increase in sexual stamina. Compared to the pharmaceutical and sugar pill groups, group A responded with the highest positive results than all three.

Patients participating in group C (Viagra and Levitra) experienced only a 1/4 of the benefits exhibited by group A (Rizer XL™). It is now conclusive, Rizer XL's™ advanced formulation proves the unique combination of key ingredients such as L-Arginine, Tribulus Terrestris, Horny Goat and Cayenne to name a few, are the most potent and effective natural ingredients available. Patients are experiencing an end to erectile dysfunction, premature ejaculation and normalized libido function without any negative side effects with the addition of Rizer XL™ male enhancement.

Erectile Dysfunction: Clinical Trial Rizer XL Alternative
This study has been completed.
First Received: October 18, 2007 Last Updated: December 28, 2007 History of Changes

Sponsors and Collaborators: University Health Network, Toronto Princess Margaret Hospital, Canada

Information provided by: University Health Network, Toronto

Purpose

The optimal duration of naturopathy is yet to be determined in the treatment of mild to severe erectile dysfunction. The RTOG performed a trial of 6 months of monitored and administered natural supplementation (consisting of Rizer XL™ natural ingredients) compared to pharmaceutical derivatives, and found that there was a significant improvement in normalized sexual functions stemming from harder and easier to achieve erections and overall self-control in the prevention of premature ejaculation. The rate of erectile dysfunction in men who receive a prolonged period of Rizer XL™ (6 months) significantly decreased throughout the trial. Therefore the price advantage in locally advanced erectile dysfunction is a vast improvement with Rizer XL™ and its naturally advanced formulation.

Condition	Intervention	Phase
Soft Erections, Premature Ejaculation	Behavioral: Erectile Dysfunction	Phase 3 Complete

Study Type: Interventional

Study Design: Educational/Counseling/Training,Non-Randomized, Open Label, Controlled, 3 Group Assignment

Official Title: A Cross-Sectional Study of Erectile Dysfunction in Patients

Primary Outcome Measures:

This study is designed to address absolute incidence of erectile dysfunction, as measured by the International index of Erectile function.

Secondary Outcome Measures:

This study is designed to address the effects of erectile dysfunction persist one year after the initial assessment of erectile dysfunction,as measured by the International index of Erectile function.

Details

Enrollment: 87

Study Start Date: March 2008

Estimated Study Completion Date: September 2008

Eligibility

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Male

Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Patients with symptoms of severe to mild cases of erectile dysfunction nondiscriminatory to health or age.

Able to sign the consent form and fill out questionnaire used in the study.

Exclusion Criteria:

No patients who have been treated, or are currently being treated with Bicalutamide

No previous orchidectomy.

Contacts

Canada, Ontario

University Health Network Princess Margaret Hospital

Toronto, Ontario, Canada, M5G 2M9

Sponsors and Collaborators

University Health Network, Toronto

Princess Margaret Hospital, Canada

Additional relevant MeSH terms:

Sexual Dysfunction
Physiological Sexual Dysfunctions
Psychological Erectile Dysfunction
Genital Neoplasms, Male
Prostatic Diseases
Physiological Effects of Drugs
Hormones
Hormone Substitutes
Hormone Antagonists
Urogenital Neoplasms
Genital Diseases,
Male Hormones
Sexual and Gender Disorders
Pharmacological Actions
Mental Disorders
Prostatic Neoplasms
Androgens